Interview with Frederic Dufour, General Manager, Biocodex Russia
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Address: 119019, г. Москва, ул. Новый Арбат д. 21,Russia
Tel: +7 (495) 783-26-80
Biocodex is an independent, family-owned French pharmaceutical company founded in 1953 by Michel Hublot and Francois Vallet.
We are present in more than 100 countries of the world through subsidiaries and partner companies.
We specialize in several therapeutic areas, namely:
– gastroenterology;
– neurology and psychiatry;
– pain treatment.
Our mission: to develop and make accessible to doctors and their patients effective and safe products which improve the health and quality of life of patients.
Biocodex in Russia
Biocodex drugs have been present in Russia since 1996.
In July 2008 the Biocodex company opened its representative office in Russia with head office in Moscow and 14 major cities covered.
Since 2009 the company promotes pharmaceuticals of a French ophthalmic company Laboratoires Thea, a European leader in the sphere of ophthalmology.
We specialize in several therapeutic areas, namely:
– gastroenterology;
– neurology and psychiatry;
– pain treatment.
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here